抗细胞因子疗法在系统性红斑狼疮中的应用。
Anticytokine therapies in systemic lupus erythematosus.
机构信息
Division of Rheumatology, Department of Medicine, University of California Los Angeles, 1000 Veteran Avenue 32-59, Los Angeles, CA 90095-1670, USA.
出版信息
Immunotherapy. 2010 Jul;2(4):575-82. doi: 10.2217/imt.10.29.
Abstract
The dysfunctional immune response that characterizes systemic lupus erythematosus (SLE) associates with an unbalanced production of soluble mediators that are crucial in promoting and sustaining chronic inflammation. The successful use of biologics in several autoimmune diseases has led to studies in SLE aimed at contrasting the proinflammatory responses that contribute to tissue and organ damage in the disease. Several approaches have been developed and tested as potential therapeutic agents in SLE in preclinical studies and in clinical trials. This article provides an overview on antibody-based approaches in SLE that, although preliminary, have the potential to expand the current therapeutic possibilities in the disease.
摘要
系统性红斑狼疮（SLE）的特征是免疫功能失调，这与可溶性介质的失衡产生有关，这些介质在促进和维持慢性炎症中起着至关重要的作用。生物制剂在几种自身免疫性疾病中的成功应用促使人们对 SLE 进行了研究，旨在对比那些导致疾病组织和器官损伤的促炎反应。在临床前研究和临床试验中，已经开发和测试了几种方法作为 SLE 的潜在治疗药物。本文概述了 SLE 中的基于抗体的治疗方法，尽管这些方法还处于初步阶段，但有可能扩大该疾病的现有治疗可能性。
相似文献
1
Anticytokine therapies in systemic lupus erythematosus.抗细胞因子疗法在系统性红斑狼疮中的应用。
Immunotherapy. 2010 Jul;2(4):575-82. doi: 10.2217/imt.10.29.
2
Antibody-based therapies in systemic lupus erythematosus.系统性红斑狼疮的抗体疗法。
Mini Rev Med Chem. 2009 Jun;9(7):829-46. doi: 10.2174/138955709788452568.
3
Cytokines as therapeutic targets in SLE.细胞因子作为治疗 SLE 的靶点。
Nat Rev Rheumatol. 2010 Jun;6(6):339-47. doi: 10.1038/nrrheum.2010.64. Epub 2010 May 4.
4
Lupus, the current therapeutic approaches.狼疮，当前的治疗方法。
Drugs Today (Barc). 2011 Apr;47(4):289-302. doi: 10.1358/dot.2011.47.4.1583186.
5
Anticytokine therapy in systemic lupus erythematosus.抗细胞因子疗法治疗红斑狼疮。
Lupus. 2010 Oct;19(12):1460-7. doi: 10.1177/0961203310376955.
6
Anti-cytokine therapy in systemic lupus erythematosus.系统性红斑狼疮的抗细胞因子治疗
Lupus. 2005;14(3):189-91. doi: 10.1191/0961203305lu2134oa.
7
Monoclonal antibodies in the treatment of systemic lupus erythematosus.单克隆抗体在系统性红斑狼疮治疗中的应用
Curr Drug Targets. 2009 Jan;10(1):26-37. doi: 10.2174/138945009787122833.
8
Biologicals for the treatment of systemic lupus erythematosus?治疗系统性红斑狼疮的生物制剂？
Ann Med. 2012 May;44(3):225-32. doi: 10.3109/07853890.2011.561362. Epub 2011 Apr 15.
9
New biologic therapy for systemic lupus erythematosus.治疗系统性红斑狼疮的新型生物疗法。
Curr Opin Pharmacol. 2013 Jun;13(3):405-12. doi: 10.1016/j.coph.2013.04.005. Epub 2013 May 7.
10
Neutrophils in the Pathogenesis of Rheumatoid Arthritis and Systemic Lupus Erythematosus: Same Foe Different M.O.中性粒细胞在类风湿关节炎和系统性红斑狼疮发病机制中的作用：相同的敌人，不同的策略
Front Immunol. 2021 Mar 4;12:649693. doi: 10.3389/fimmu.2021.649693. eCollection 2021.
引用本文的文献
1
Cytokines unveiled: their impact on oral and multisystem features of lupus erythematosus.细胞因子揭秘：它们对红斑狼疮口腔及多系统特征的影响
Front Immunol. 2025 Jul 28;16:1585280. doi: 10.3389/fimmu.2025.1585280. eCollection 2025.
2
Altered expression of miR-125a and dysregulated cytokines in systemic lupus erythematosus: Unveiling diagnostic and prognostic markers.系统性红斑狼疮中miR-125a表达改变及细胞因子失调：揭示诊断和预后标志物
World J Exp Med. 2023 Dec 20;13(5):102-114. doi: 10.5493/wjem.v13.i5.102.
3
Immunoprofiling of cytokines, chemokines, and growth factors in female patients with systemic lupus erythematosus- a pilot study.对系统性红斑狼疮女性患者细胞因子、趋化因子和生长因子的免疫组化分析——一项初步研究。
BMC Immunol. 2023 Jun 27;24(1):13. doi: 10.1186/s12865-023-00551-6.
4
Imbalance of helper T cell type 1, helper T cell type 2 and associated cytokines in patients with systemic lupus erythematosus: A meta-analysis.系统性红斑狼疮患者辅助性T细胞1型、辅助性T细胞2型及相关细胞因子的失衡：一项荟萃分析。
Front Pharmacol. 2022 Sep 29;13:988512. doi: 10.3389/fphar.2022.988512. eCollection 2022.
5
Placental damage in pregnancies with systemic lupus erythematosus: A narrative review.系统性红斑狼疮妊娠中的胎盘损伤：叙述性综述。
Front Immunol. 2022 Aug 17;13:941586. doi: 10.3389/fimmu.2022.941586. eCollection 2022.
6
Role of the innate and adaptive immune responses in the pathogenesis of systemic lupus erythematosus.固有免疫和适应性免疫应答在系统性红斑狼疮发病机制中的作用。
Inflamm Res. 2022 Jun;71(5-6):537-554. doi: 10.1007/s00011-022-01554-6. Epub 2022 Mar 17.
7
Cytokines as Biomarkers in Systemic Lupus Erythematosus: Value for Diagnosis and Drug Therapy.细胞因子作为系统性红斑狼疮的生物标志物：在诊断和药物治疗中的价值。
Int J Mol Sci. 2021 Oct 20;22(21):11327. doi: 10.3390/ijms222111327.
8
Drugs in early clinical development for Systemic Lupus Erythematosus.用于系统性红斑狼疮早期临床开发的药物。
Expert Opin Investig Drugs. 2016;25(5):573-83. doi: 10.1517/13543784.2016.1162291. Epub 2016 Apr 7.
9
Role of toll-like receptor 4 on lupus lung injury and atherosclerosis in LPS-challenge ApoE⁻/⁻ mice.Toll样受体4在脂多糖刺激的载脂蛋白E基因敲除小鼠狼疮性肺损伤和动脉粥样硬化中的作用
Clin Dev Immunol. 2013;2013:476856. doi: 10.1155/2013/476856. Epub 2013 Sep 15.
10
Novel transcriptional regulation of VEGF in inflammatory processes.在炎症过程中 VEGF 的新型转录调控。
J Cell Mol Med. 2013 Mar;17(3):386-97. doi: 10.1111/jcmm.12020. Epub 2013 Feb 18.
本文引用的文献
1
Update on emerging drug therapies for systemic lupus erythematosus.新兴药物治疗系统性红斑狼疮的研究进展。
Expert Opin Emerg Drugs. 2010 Mar;15(1):53-70. doi: 10.1517/14728210903535878.
2
Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study.托珠单抗治疗系统性红斑狼疮：来自一项开放标签I期剂量递增研究的安全性、初步疗效及对循环浆细胞影响的数据
Arthritis Rheum. 2010 Feb;62(2):542-52. doi: 10.1002/art.27221.
3
Human Genome Sciences trial data wow lupus community.
Nat Biotechnol. 2009 Sep;27(9):779-80. doi: 10.1038/nbt0909-779.
4
The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus.B淋巴细胞刺激因子（BLyS）在系统性红斑狼疮中的作用。
J Clin Invest. 2009 May;119(5):1066-73. doi: 10.1172/JCI38010. Epub 2009 May 1.
5
Belimumab: anti-BLyS human monoclonal antibody, anti-BLyS monoclonal antibody, BmAb, human monoclonal antibody to B-lymphocyte stimulator.贝利尤单抗：抗B淋巴细胞刺激因子人源单克隆抗体、抗B淋巴细胞刺激因子单克隆抗体、BmAb、抗B淋巴细胞刺激因子人源单克隆抗体
Drugs R D. 2008;9(3):197-202. doi: 10.2165/00126839-200809030-00008.
6
Anti-BR3 antibodies: a new class of B-cell immunotherapy combining cellular depletion and survival blockade.抗BR3抗体：一类新型的B细胞免疫疗法，兼具细胞清除和生存阻断作用。
Blood. 2007 Dec 1;110(12):3959-67. doi: 10.1182/blood-2007-04-088088. Epub 2007 Aug 8.
7
Therapeutic efficacy and safety profile of infliximab in active systemic lupus erythematosus.英夫利昔单抗治疗活动性系统性红斑狼疮的疗效和安全性
Mod Rheumatol. 2007;17(2):174-7. doi: 10.1007/s10165-006-0561-8. Epub 2007 Apr 20.
8
Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus.短期英夫利昔单抗治疗对系统性红斑狼疮自身抗体的影响。
Arthritis Rheum. 2007 Jan;56(1):274-9. doi: 10.1002/art.22327.
9
Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus.系统性红斑狼疮患者中干扰素诱导基因表达增加与疾病活动及狼疮性肾炎的关联。
Arthritis Rheum. 2006 Sep;54(9):2951-62. doi: 10.1002/art.22044.
10
Synthetic anti-BR3 antibodies that mimic BAFF binding and target both human and murine B cells.模拟BAFF结合并靶向人和小鼠B细胞的合成抗BR3抗体。
Blood. 2006 Nov 1;108(9):3103-11. doi: 10.1182/blood-2006-03-011031. Epub 2006 Jul 13.
Zotero 插件